Medical and sociodemographic factors associated with human papillomavirus (HPV) vaccination adherence among female survivors of childhood cancer

Pediatric Blood and Cancer

Volumn 62, Issue 9, 2015, Pages 1630-1636

  Klosky, James L ^a   Russell, Kathryn M ^a   Simmons, Jessica L ^a   Foster, Rebecca H ^b,c   Peck, Kelly ^a,d   Green, Daniel M ^a   Hudson, Melissa M ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b ST LOUIS CHILDREN S HOSPITAL   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

Adolescents; Human papillomavirus; Oncology; Vaccination; Young adults

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER SURVIVAL; CANCER SURVIVOR; CANCER THERAPY; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GROUPS BY AGE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MEDICATION COMPLIANCE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAPILLOMAVIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; SCHOOL CHILD; VACCINATION; WART VIRUS; YOUNG ADULT; AGE; ATTITUDE TO HEALTH; COUNSELING; HEALTH CARE SURVEY; MOTHER; MOTIVATION; NEOPLASMS; PATIENT COMPLIANCE; PHYSICIAN ATTITUDE; PSYCHOLOGY; SOCIOECONOMICS; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; SURVIVOR; UTILIZATION;

ADOLESCENT; ADULT; AGE FACTORS; CHILD; COUNSELING; FEMALE; HEALTH CARE SURVEYS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; LOGISTIC MODELS; MOTHERS; MOTIVATION; NEOPLASMS; PAPILLOMAVIRUS VACCINES; PATIENT COMPLIANCE; PHYSICIAN'S ROLE; SOCIOECONOMIC FACTORS; SURVIVORS; VACCINATION; YOUNG ADULT;

EID: 84938196636     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25539     Document Type: Article

References (35)

1. Weinstock H, Berman S, Cates W. Sexually transmitted diseases among American youth: Incidence and prevalence estimates, 2000. Perspect Sex Reprod Health 2004; 36:6-10.
2. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005; 6:204.
3. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, Markowitz LE. Prevalence of HPV infection among females in the United States. JAMA 2007; 297:813-819.
4. Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000; 151:1158-1171.
5. Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, Bocchini JA, Unger ER. Quadrivalent human papillomavirus vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56:1-24.
6. Klein NP, Hansen J, Chao C, Velicer C, Emery M, Slezak J, Lewis N, Deosaransingh K, Sy L, Ackerson B, Cheetham TC, Liaw KL, Takhar H, Jacobsen SJ. Safety of quadrivalent human papillomavirus vaccine administered routinely to females. Arch Pediatr Adolesc Med 2012; 166:1140-1148.
7. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G. HPV Vaccine Study Group. Sustained efficacy up to 4-5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial. Lancet 2006; 367:1247-1255.
8. U.S. Food and Drug Administration. FDA licenses new vaccine for prevention of cervical cancer and other diseases in females caused by human papillomavirus. Published June 8, 2008, Updated April 8, 2013, Accessed June 21, 2014. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108666.htm
9. Villa LL, Costa RLR, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koustsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ, Barr E. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6:271-278.
10. Recommended immunization schedules for persons aged 0 through 18 years - United States, 2012. MMWR Morb Mortal Wkly Rep 2012; 61:1-4.
11. U.S. Food and Drug Administration. Product approval-prescribing information [package insert] Gardasil® [human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant], Merck and Co, Inc. Published 2006, Updated March 2014, Accessed June 20, 2014. http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM094042
12. Saslow D, Castle PE, Cox JT, Davey DD, Einstein MH, Ferris DG, Goldie SJ, Harper DM, Kinney W, Moscicki AB, Noller KL, Wheeler CM, Ades T, Andrews KS, Doroshenk MK, Kahn KG, Schmidt C, Shafey O, Smith RA, Partridge EE, Garcia F. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 2007; 57:7-28.
13. Ojha RP, Tota JE, Offutt-Powell TN, Klosky JL, Minniear TD, Jackson BE, Gurney JG. Human papillomavirus-associated subsequent malignancies among long-term survivors of pediatric and young adult cancers. PLoS ONE 2013; 8:e70349. doi: 10.1371/journal.pone.0070349
14. Bhatia S, Louie AD, Bhatia R, O'Donnell MR, Fung H, Kashyap A, Krishnan A, Molina A, Nademanee A, Niland JC, Parker PA, Snyder DS, Spielberger R, Stein A, Forman SJ. Solid cancers after bone marrow transplantation. J Clin Oncol 2001; 19:464-471.
15. Sasadeusz J, Kelly H, Szer J, Schwarer AP, Mitchell H, Grigg A. Abnormal cervical cytology in bone marrow transplant receipts. Bone Marrow Transplant 2001; 28:393-397.
16. Fujimura M, Ostrow RS, Okagaki T. Implication of human papillomavirus in postirradiation dysplasia. Cancer 1991; 68:2181-2185.
17. Katz RL, Veanattukalathil S, Weiss KM. Human papillomavirus infection and neoplasia of the cervix and anogenital region in women with Hodgkin's disease. Acta Cytol 1987; 31:845-854.
18. Crawford NW, Heath JA, Ashley D, Downie P, Buttery JP. Survivors of childhood cancer: An Australian audit of vaccination status after treatment. Pediatr Blood Cancer 2010; 54:128-133.
19. Children's Oncology Group. Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers. Published October 2008. Accessed June 20, 2014. http://www.survivorshipguidelines.org/pdf/LTFUGuidelines.pdf
20. Brabin L, Roberts SA, Farzaneh F, Kitchener HC. Future acceptance of adolescent human papillomavirus vaccination: A survey of parental attitudes. Vaccine 2006; 24:3087-3094.
21. Werba BE, Hobbie W, Kazak AE, Ittenbach RF, Reilly AF, Meadows AT. Classifying the intensity of pediatric cancer treatment protocols: The intensity of treatment rating scale 2.0 (ITR-2). Pediatr Blood Cancer 2007; 48:673-677.
22. Hudson MM, Ness KK, Gurney JG, Mulrooney DA, Chemaitilly W, Krull KR, Green DM, Armstrong GT, Nottage KA, Jones KE, Sklar CA, Srivastava DK, Robison LL. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA 2013; 309:2371-2381.
23. Ness KK, Krull KR, Jones KE, Mulrooney DA, Armstrong GT, Green DM, Chemaitilly W, Smith WA, Wilson CL, Sklar CA, Shelton K, Srivastava DK, Ali S, Robison LL, Hudson MM. Physiologic frailty as a sign of accelerated aging among adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort Study. J Clin Oncol 2013; 31:4496-4503.
24. Centers for Disease Control and Prevention. National and state vaccination coverage among adolescents aged 13-17 years - United States, 2012. MMWR Morb Mortal Wkly Rep 2013; 62:685-693.
25. Williams WW, Lu PJ, O'Halloran A, Bridges CB, Pilishvili T, Hales CM, Markowitz LE. Noninfluenza vaccination coverage among adults - United States, 2012. MMWR Morb Mortal Wkly Rep 2014; 63:95-102.
26. Department of Health and Human Services. Healthy people 2020: Improving the health of Americans. Accessed June 22, 2014. http://www.healthypeople.gov/2020/default.aspx
27. Kessels SJ, Marshall HS, Watson M, Braunack-Mayer AJ, Reuzel R, Tooher RL. Factors associated with HPV vaccine uptake in teenage girls: A systematic review. Vaccine 2012; 30:3546-3556.
28. GAVI Alliance. Human papillomavirus vaccine support. Accessed June 22, 2014. http://www.gavialliance.org/support/nvs/human-papillomavirus-vaccine-support/
29. Reiter PL, Brewer NT, Gottlieb SL, McRee AL, Smith JS. Parents' health beliefs and HPV vaccination of their adolescent daughters. Soc Sci Med 2009; 69:475-480.
30. Vadaparampil ST, Kahn JA, Salmon D, Lee JH, Quinn GP, Roetzheim R, Bruder K, Malo TL, Proveaux T, Zhao X, Halsey N, Giuliano AR. Missed clinical opportunities: Provider recommendations for HPV vaccination for 11-12 year old girls are limited. Vaccine 2011; 29:8634-8641.
31. Becker MH. The Health Belief Model and personal health behavior. Health Educ Monogr 1974; 2:324-473.
32. Griffioen AM, Glynn S, Mullins TK, Zimet GD, Rosenthal SL, Fortenberry JD, Kahn JA. Perspectives on decision making about human papillomavirus vaccination among 11- to 12-year old girls and their mothers. Clin Pediatr (Phila) 2012; 51:560-568.
33. Esposito S, Cecinati V, Brescia L, Principi N. Vaccinations in children with cancer. Vaccine 2010; 28:3278-3284.
34. Niccolai LM, Mehta NR, Hadler JL. Racial/ethnic and poverty disparities in human papillomavirus vaccination completion. Am J Prev Med 2011; 41:428-433.
35. Stokley S, Jeyarajah J, Yankey D, Cano M, Gee J, Roark J, Curtis RC, Markowitz L, Immunization Services Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention. Human papillomavirus vaccination coverage among adolescents, 2007-2013, and post-licensure vaccine safety monitoring, 2006-2014-United States. MMWR Morb Mortal Wkly Rep 2014; 63:620-624.